United Therapeutics Corporation History

Please see Important Safety Information for our FDA approved products under the Research and Medicine tab.

2024

First successful transplant of a xenokidney from a pig with ten gene edits 500th lung transplant using UT’s EVLP service
Read the Press Release

2023

United Therapeutics acquires IVIVA Medical Inc.

2022

2021

2020

Increase Study logo for Tyvaso

2019

2018

2017

2016

Launch of Unither 2.0, Major Pipeline Expansion
UT obtains $1 billion unsecured line of credit

2015

UT enters into collaboration with Mayo Clinic to build and operate an ex-vivo lung perfusion center in Jacksonville, Florida
Read the Press Release

2014

UT opens Regenerative Medicine Lab in Research Triangle Park, North Carolina, with a focus on manufacturing lungs and lung lobes for transplant
UT and DEKA Research & Development Corp. enter into an agreement to develop a next-generation subcutaneous pump for Remodulin®, which ultimately resulted in the Remunity® Pump for Remodulin®
Read the Press Release

2013

UT annual revenues surpass $1 billion

2011

Adcirca® becomes most prescribed drug for PAH
United Therapeutics acquires Revivicor xenotransplantation program
Annual Report Soundtrack
01 – “Dear Shareholders” performed by the Alan Scott Band
02 – “Live it up” performed by the Alan Scott Band
03 – “2011” performed by the Alan Scott Band
04 – “Helicopter” performed by the Alan Scott Band

2010

United Therapeutics launches collaboration with National Cancer Institute to develop a monoclonal antibody for treatment of high-risk neuroblastoma, which is today known as Unituxin®

2009

UT surpasses $1 billion in assets

2008

UT in-licenses U.S. commercialization rights to Adcirca® for PAH from Eli Lilly and Company
Read the Press Release

2007

2006

2005

Remodulin®® approved by 23 countries in the European Union for the treatment of PAH to improve exercise capacity by subcutaneous infusion
Read the Press Release

2004

FDA approves expansion of Remodulin® label to include treatment of PAH by intravenous infusion
Read the Press Release

2003

UT commences first human clinical trial of an oral formulation of treprostinil

2002

Remodulin® approved in the United States, Canada and Israel to treat PAH by subcutaneous infusion
Visit Remodulin Website

2001

2000

UT submits new drug application to FDA for Remodulin® to treat pulmonary arterial hypertension

1999

United Therapeutics acquires rights to treprostinil from Glaxo Wellcome Inc.
United Therapeutics acquires Synquest, Inc., providing in-house capacity and expertise to manufacture treprostinil

1997

Initial public offering (Nasdaq:UTHR), priced at $12.00 per share

1996

United Therapeutics founded by Martine Rothblatt to find a cure for her daughter's life- threatening condition, now known as pulmonary arterial hypertension